Eli Lilly Ends Covid-19 Antibody Trial After Finding It’s Unlikely To Help Hospitalized Patients

Topline

Eli Lilly said Monday that it will end a U.S.-based clinical trial for its coronavirus antibody treatment because the data indicates the treatment is unlikely to help coronavirus patients recover from advanced stages of the disease, a move which comes two weeks after it paused the trial citing a potential safety concern.

Key Facts

Tangent

President Trump has claimed an experimental antibody cocktail made by Regeneron that he was given was a “cure” and he has said positive things about Eli Lilly’s antibody therapy in recent videos. Trump’s confidant, former New Jersey governor Chris Christie, said he was given Eli Lily’s experimental antibody treatment when he was hospitalized for coronavirus this month. He had attended the September 26 event hosted at the White House to announce judge Amy Coney Barrett’s nomination to the Supreme Court. At least 14 people who attended have since tested positive. 

Further Reading

Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To ‘Potential Safety Concern’ (Forbes)

Report: Eli Lilly In Violation Of FDA Manufacturing Standards At Plant Preparing To Produce Covid Treatment (Forbes)

Full coverage and live updates on the Coronavirus